AR070158A1 - Compuesto de benzamida composicion farmaceutica que lo comprende y su uso para la manufactura de un medicamento util para antagonizar selectivamente los rceptores opioides kappa - Google Patents

Compuesto de benzamida composicion farmaceutica que lo comprende y su uso para la manufactura de un medicamento util para antagonizar selectivamente los rceptores opioides kappa

Info

Publication number
AR070158A1
AR070158A1 ARP090100098A ARP090100098A AR070158A1 AR 070158 A1 AR070158 A1 AR 070158A1 AR P090100098 A ARP090100098 A AR P090100098A AR P090100098 A ARP090100098 A AR P090100098A AR 070158 A1 AR070158 A1 AR 070158A1
Authority
AR
Argentina
Prior art keywords
manufacture
pharmaceutical composition
kappa
rceptors
benzamida
Prior art date
Application number
ARP090100098A
Other languages
English (en)
Spanish (es)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of AR070158A1 publication Critical patent/AR070158A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
ARP090100098A 2008-01-22 2009-01-13 Compuesto de benzamida composicion farmaceutica que lo comprende y su uso para la manufactura de un medicamento util para antagonizar selectivamente los rceptores opioides kappa AR070158A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08380012 2008-01-22
US3912108P 2008-03-25 2008-03-25

Publications (1)

Publication Number Publication Date
AR070158A1 true AR070158A1 (es) 2010-03-17

Family

ID=40876972

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090100098A AR070158A1 (es) 2008-01-22 2009-01-13 Compuesto de benzamida composicion farmaceutica que lo comprende y su uso para la manufactura de un medicamento util para antagonizar selectivamente los rceptores opioides kappa

Country Status (32)

Country Link
US (2) US7709522B2 (OSRAM)
EP (1) EP2252581B1 (OSRAM)
JP (1) JP5345637B2 (OSRAM)
KR (1) KR101172170B1 (OSRAM)
CN (1) CN101925576B (OSRAM)
AR (1) AR070158A1 (OSRAM)
AU (1) AU2009206653B2 (OSRAM)
BR (1) BRPI0907382B8 (OSRAM)
CA (1) CA2713025C (OSRAM)
CO (1) CO6290644A2 (OSRAM)
CY (1) CY1113071T1 (OSRAM)
DK (1) DK2252581T3 (OSRAM)
DO (1) DOP2010000222A (OSRAM)
EA (1) EA017484B1 (OSRAM)
EC (1) ECSP10010365A (OSRAM)
ES (1) ES2388708T3 (OSRAM)
HR (1) HRP20120558T1 (OSRAM)
IL (1) IL206038A (OSRAM)
JO (1) JO2797B1 (OSRAM)
MA (1) MA32751B1 (OSRAM)
MX (1) MX2010007849A (OSRAM)
MY (1) MY163014A (OSRAM)
NZ (1) NZ586225A (OSRAM)
PE (1) PE20091317A1 (OSRAM)
PL (1) PL2252581T3 (OSRAM)
PT (1) PT2252581E (OSRAM)
SI (1) SI2252581T1 (OSRAM)
TN (1) TN2010000306A1 (OSRAM)
TW (1) TWI422369B (OSRAM)
UA (1) UA100715C2 (OSRAM)
WO (1) WO2009094260A1 (OSRAM)
ZA (1) ZA201003908B (OSRAM)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201070876A1 (ru) * 2008-01-22 2011-04-29 Такеда Фармасьютикал Компани Лимитед Трициклические соединения, обладающие антагонистической активностью по отношению к кортикотропин-высвобождающему фактору, и содержащие их фармацевтические композиции
JO2797B1 (en) * 2008-01-22 2014-03-15 ايلي ليلي اند كومباني Selective opioid receptor antagonist kappa
US9345703B2 (en) 2011-09-15 2016-05-24 University Of Kansas Kappa opioid receptor effectors and uses thereof
WO2013042054A1 (en) 2011-09-19 2013-03-28 Carmel - Haifa University Economic Corporation Ltd. Buprenorphine for the treatment of acute suicidality
JP6061948B2 (ja) 2011-12-09 2017-01-18 リサーチ トライアングル インスティテュート κオピオイド受容体アンタゴニストとしての１−置換４−アリールピペラジン
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神分裂病を処置するための方法および組成物
US9283196B1 (en) 2013-01-30 2016-03-15 MediSynergics, LLC Cycloalkyl-diamines for CNS disorders
JP2016519161A (ja) * 2013-05-24 2016-06-30 アルカームス ファーマ アイルランド リミテッド モルファン及びモルフィナン類似物及び使用の方法
US10316021B2 (en) 2016-11-28 2019-06-11 Pfizer Inc. Heteroarylphenoxy benzamide kappa opioid ligands
CN110914262B (zh) 2017-03-17 2024-04-05 斯克里普斯研究所 κ阿片受体拮抗剂以及与其相关的产品和方法
JP6480616B1 (ja) 2018-02-08 2019-03-13 有限会社 ディオン光学技研 照準スコープ
US11266627B1 (en) 2021-05-04 2022-03-08 Janssen Pharmaceuticals, Inc. Compositions and methods for the treatment of depression
CN114195693A (zh) * 2020-09-17 2022-03-18 广东东阳光药业有限公司 一种酰胺化合物的晶型及其制备方法
CN114591211B (zh) * 2020-12-04 2025-10-21 广东东阳光药业股份有限公司 一种酰胺化合物的共晶及其制备方法
WO2022234457A1 (en) 2021-05-04 2022-11-10 Janssen Pharmaceuticals, Inc. Compositions and methods for the treatment of depression
US12161622B2 (en) 2021-05-04 2024-12-10 Janssen Pharmaceuticals, Inc. Compositions and methods for the treatment of depression
IL314176A (en) * 2022-01-10 2024-09-01 Janssen Pharmaceuticals Inc Compositions and methods for treating depression
US20250221960A1 (en) * 2022-01-10 2025-07-10 Janssen Pharmaceuticals, Inc. Compositions and methods for the treatment of depression
PE20242109A1 (es) * 2022-03-07 2024-10-28 Janssen Pharmaceuticals Inc Formas puras de aticaprant cristalino
CA3254546A1 (en) * 2022-03-07 2023-09-14 Janssen Pharmaceuticals, Inc. COMPOSITIONS CONTAINING ATICAPRANT
WO2023170550A1 (en) 2022-03-07 2023-09-14 Janssen Pharmaceuticals, Inc. Polymorph forms of aticaprant for use in treating major depressive disorder
JP7176142B1 (ja) 2022-03-09 2022-11-21 直迪 清瀬 各アルコール飲用者において飲用し得るアルコール飲料の種類に対応する飲用量の上限値に関する情報を提供するシステム

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5457208A (en) 1993-06-21 1995-10-10 Regents Of The University Of Minnesota Kappa opioid receptor antagonists
CN1164590C (zh) * 1999-05-12 2004-09-01 弗·哈夫曼-拉罗切有限公司 咪唑二氮杂�衍生物
AU2001292164A1 (en) * 2000-10-05 2002-04-15 Hanns Mohler Selective anxiolytic therapeutic agents
EP1353665A4 (en) 2000-12-21 2004-05-06 Mclean Hospital Corp Treatment of depression
US6974824B2 (en) 2001-01-08 2005-12-13 Research Triangle Institute Kappa opioid receptor ligands
KR100865410B1 (ko) * 2002-03-28 2008-10-24 위시스 테크놀로지 파운데이션, 인크. 진정 및 운동실조 효과가 감소된 항불안제
ES2305491T3 (es) 2002-09-19 2008-11-01 Eli Lilly And Company Eteres de diarilo como antagonistas de receptores de opioides.
DE602004016127D1 (de) 2003-03-07 2008-10-09 Lilly Co Eli Antagonisten der opioidrezeptoren
ATE377589T1 (de) 2003-03-07 2007-11-15 Lilly Co Eli 6-substituierte nikotinamidderivate als opioidrezeptorantagonisten
CA2549009A1 (en) 2003-12-12 2005-07-07 Eli Lilly And Company Opioid receptor antagonists
EP1699783B1 (en) 2003-12-22 2012-07-25 Eli Lilly And Company Opioid receptor antagonists
WO2005090286A1 (en) 2004-03-12 2005-09-29 Eli Lilly And Company Opioid receptor antagonists
CA2559207A1 (en) 2004-03-12 2005-09-29 The Mclean Hospital Corporation Salvinorin derivatives and uses thereof
EP1730140B1 (en) 2004-03-12 2008-06-25 Eli Lilly And Company Opioid receptor antagonists
CA2557794A1 (en) 2004-03-15 2005-10-06 Eli Lilly And Company Opioid receptor antagonists
CA2558030A1 (en) 2004-03-15 2005-09-29 Eli Lilly And Company 4- (5- (aminomethyl) -indole-1-ylmethyl) -benzamide derivatives and related compounds as opioid receptor antagonists for the treatment of obesity
WO2007067714A2 (en) 2005-12-08 2007-06-14 The Mclean Hospital Corporation Treatment of sequelae of psychiatric disorders
HRP20100113T1 (hr) 2006-04-04 2010-04-30 Emodys Gmbh Upotreba pripravaka koji sadrže antagonist kapa-opioidnog receptora, namijenjenih liječenju disocijativnih poremećaja
WO2008021851A2 (en) 2006-08-09 2008-02-21 Smithkline Beecham Corporation Novel compounds as antagonists or inverse agonists for opioid receptors
US8633175B2 (en) 2006-08-09 2014-01-21 Glaxosmithkline Llc Compounds as antagonists or inverse agonists at opioid receptors
CA2662766C (en) 2006-09-08 2011-08-09 Pfizer Products Inc. Diaryl ether derivatives and uses thereof
JO2797B1 (en) * 2008-01-22 2014-03-15 ايلي ليلي اند كومباني Selective opioid receptor antagonist kappa

Also Published As

Publication number Publication date
CN101925576B (zh) 2013-02-06
ECSP10010365A (es) 2010-08-31
EA201070877A1 (ru) 2010-12-30
US20090186873A1 (en) 2009-07-23
AU2009206653B2 (en) 2013-07-18
EA017484B1 (ru) 2012-12-28
US8173695B2 (en) 2012-05-08
HK1146822A1 (en) 2011-07-15
MY163014A (en) 2017-07-31
TWI422369B (zh) 2014-01-11
UA100715C2 (ru) 2013-01-25
MX2010007849A (es) 2010-08-09
US20100197669A1 (en) 2010-08-05
DK2252581T3 (da) 2012-07-16
PL2252581T3 (pl) 2012-10-31
TW200936129A (en) 2009-09-01
DOP2010000222A (es) 2015-11-15
NZ586225A (en) 2012-05-25
IL206038A0 (en) 2010-11-30
EP2252581A1 (en) 2010-11-24
BRPI0907382A2 (pt) 2015-07-21
AU2009206653A1 (en) 2009-07-30
KR101172170B1 (ko) 2012-08-07
BRPI0907382B8 (pt) 2021-05-25
JP2011524850A (ja) 2011-09-08
PT2252581E (pt) 2012-08-31
MA32751B1 (fr) 2011-11-01
ZA201003908B (en) 2011-11-30
US7709522B2 (en) 2010-05-04
CY1113071T1 (el) 2016-04-13
ES2388708T3 (es) 2012-10-17
WO2009094260A1 (en) 2009-07-30
CA2713025C (en) 2012-12-04
TN2010000306A1 (en) 2011-11-11
JO2797B1 (en) 2014-03-15
KR20100095639A (ko) 2010-08-31
HRP20120558T1 (hr) 2012-10-31
IL206038A (en) 2013-11-28
SI2252581T1 (sl) 2012-09-28
CN101925576A (zh) 2010-12-22
BRPI0907382B1 (pt) 2020-03-10
CA2713025A1 (en) 2009-07-30
CO6290644A2 (es) 2011-06-20
PE20091317A1 (es) 2009-09-03
EP2252581B1 (en) 2012-06-20
JP5345637B2 (ja) 2013-11-20

Similar Documents

Publication Publication Date Title
AR070158A1 (es) Compuesto de benzamida composicion farmaceutica que lo comprende y su uso para la manufactura de un medicamento util para antagonizar selectivamente los rceptores opioides kappa
PE20121820A1 (es) (2s,3r)-n-(2-((3-piridinil)metil)-1-azabiciclo[2.2.2]oct-3-il)benzofuran-2-carboxamida, formas de sales novedosas de ella, y metodos de uso de ella
CO6321265A2 (es) Compuestos de 2-amido-3-metil pirrolo pirimidinona fenilo -sustituidos como inhibidores bace-1 composiciones y su uso
BR112015014222A2 (pt) composto, composição farmacêutica, uso de um composto, método para o tratamento de anemia e composição farmacêutica
CL2009000815A1 (es) Compuestos derivados de fenilhidroximetilpirrolidina, agonista del recptor adrenergico beta 3; composicion farmaceutica que los comprende; uso en el tratamiento de vejiga hiperactiva, incontinencia urinaria por impulso y urgencia urinaria.
CO6470846A2 (es) Derivados aminobut´ricos sustituidos como inhibidores de neprilisina
ECSP12011799A (es) Compuestos de espiropiperidina y uso farmacéutico de los mismos
UY29825A1 (es) Derivados sustituidos de 3h-imidazol-(4,5 b (beta))piridina-2-il benzoatos y benzamidas, composiciones farmacéuticas que los contienen y aplicaciones
PE20140099A1 (es) Derivados de azetidina y ciclobutano como inhibidores de jak
CO6470847A2 (es) Derivados amino-propiónicos sustituidos como inhibidores de neprilisina
ECSP088973A (es) Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3)
CR20150114A (es) Composición farmacéutica recubierta que contiene regorafenib
AR077638A1 (es) Compuesto de (metanosulfonil -piperidin )-( alcoxi-aril) -tetrahidro- piridina , composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para el tratamiento de diabetes u obesidad
CL2013003597A1 (es) Compuestos derivados de n-[4-(2-oxo-1,2-dihidropiridin-4-il)bencil]benzamida; composicion farmaceutica y su uso para tratar la dependencia quimica a un agente productor de dopamina como cocaina, opiaceos, anfetaminas, nicotina y alcohol y para tratar la obesidad.
CL2008003789A1 (es) Compuestos derivados de bencimidazol sustituido por carboxilo o por hidroxilo, moduladores selectivos del receptor x de farnesoide (fxr); proceso de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la diabetes, dislipidemia, sindrome metabolico, cancer, alzheimer.
MA37886A1 (fr) Nouvelles pyridinones bicycliques
CL2010000059A1 (es) (2s,3r)-n-(2-((3-piridinil)metil)-1-azabiciclo[2.2.2]oct-3-il)-3,5-diflurobenzamida o una sal farmaceuticamente aceptable; forma polimorfica de la sal clorhidrato; composicion farmaceutica; y su uso para tratar una enfermedad del sistema nervioso central tal como dolor, sindrome metabolico, inflamacion, alzheimer.
UY37837A (es) Nuevos compuestos heterocíclicos como inhibidores de cdk8/19
AR078951A1 (es) Esferoides de farmacos revestidos y usos de los mismos para la eliminacion o reduccion de afecciones tales como emesis y diarrea
ECSP10010606A (es) Derivados de quinuclidina como antagonistas de receptores muscarinicos m3
ECSP22032016A (es) Inhibidor de irak y método de preparación para el mismo y uso del mismo
AR079343A1 (es) Compuesto de acido 2-amino-4-(4h-1,2,4-triazol-3-ilsulfanil)biciclo[3.1.0]hexano-2,6-dicarboxilico, composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para tratar un trastorno psiquiatrico
UY31824A (es) Nuevos compuestos
AR114930A1 (es) Composición farmacéutica
BR112012006233B8 (pt) composto de fórmula i, composição farmacêutica e usos de um composto

Legal Events

Date Code Title Description
FC Refusal